Amplia Therapeutics (ASX:ATX) has provided an update on the ongoing ACCENT trial investigating its FAK inhibitor narmafotinib in advanced pancreatic cancer. …
Amplia announces second confirmed complete response in ACCENT trial
June 19, 2025 Australian Biotech
Latest Video
New Stories
-
Amplia announces second confirmed complete response in ACCENT trial
June 19, 2025 - - Australian Biotech -
NZ Government expands access to melatonin and psilocybin
June 18, 2025 - - Latest News -
Imugene announces US patent allowance for onCARlytics
June 18, 2025 - - Australian Biotech -
Pilot study confirms adjunct NB-UVB needed to activate repigmentation in vitiligo
June 18, 2025 - - Australian Biotech -
One CSL innovation that allows for a direct and timely comparison
June 18, 2025 - - Latest News -
New survey reveals role of credit cards and borrowing in healthcare access
June 18, 2025 - - Latest News -
Montu pushes for national standards at Productivity Commission inquiry
June 17, 2025 - - Latest News